Renaud Sabatier

Renaud Sabatier

Marseille, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 128 publications

Clinical outcomes and prognostic factors in advanced high-grade platinum-resistant ovarian carcinoma: evidence from the ESME real-world cancer database.

Clinical outcomes and prognostic factors in advanced high-grade platinum-resistant ovarian carcinoma: evidence from the ESME real-world cancer database.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: May 15, 2026

French recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2024-2025: Management of advanced cervical cancer

French recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2024-2025: Management of advanced cervical cancer

Journal: Bulletin du cancer

Published: October 24, 2025

Surgical approach and maintenance therapy in advanced low-grade serous ovarian cancer: Insights from the French ESME database.

Surgical approach and maintenance therapy in advanced low-grade serous ovarian cancer: Insights from the French ESME database.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: July 25, 2025

Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer.

Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: May 15, 2025

Role of platinum-free interval (PFI) and maintenance therapies in recurrent ovarian cancer to explain survival. An analysis from the French real-world ESME Ovarian Database.

Role of platinum-free interval (PFI) and maintenance therapies in recurrent ovarian cancer to explain survival. An analysis from the French real-world ESME Ovarian Database.

Journal: Gynecologic oncology

Published: March 18, 2025

BTN2A1 acquisition through trogocytosis enhances Vγ9Vδ2 T cell cytotoxicity against autologous and cancer cells.

BTN2A1 acquisition through trogocytosis enhances Vγ9Vδ2 T cell cytotoxicity against autologous and cancer cells.

Journal: Cell reports

Published: March 12, 2025

Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?

Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?

Journal: Cancer treatment reviews

Published: January 24, 2025

Presentation of the ENDO-SFOG CAMPUS app: An easy therapeutic decision support app in endometrial cancer created by the French Society of Young Gynecological Oncologists (SFOG Campus).

Presentation of the ENDO-SFOG CAMPUS app: An easy therapeutic decision support app in endometrial cancer created by the French Society of Young Gynecological Oncologists (SFOG Campus).

Journal: Journal of gynecology obstetrics and human reproduction

Published: January 11, 2025

Immune landscape and TAM density in endometrial cancer: implications for immune checkpoint inhibitors efficacy.

Immune landscape and TAM density in endometrial cancer: implications for immune checkpoint inhibitors efficacy.

Journal: Therapeutic advances in medical oncology

Published: December 27, 2024

Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study.

Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study.

Journal: Journal for immunotherapy of cancer

Published: November 25, 2024

ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer.

ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 06, 2024

Tertiary Lymphoid Structures Are Associated with Enhanced Macrophage Activation and Immune Checkpoint Expression and Predict Outcome in Cervical Cancer.

Tertiary Lymphoid Structures Are Associated with Enhanced Macrophage Activation and Immune Checkpoint Expression and Predict Outcome in Cervical Cancer.

Journal: Cancer immunology research

Published: October 09, 2024

Showing 1-12 of 128

Last Updated: 09/26/2026